Signaling Pathway
Sevirumab (MSL-109) is a human IgG1 monoclonal antibody designed to neutralize cytomegalovirus (CMV). This antibody specifically targets CMV glycoprotein H (gH) complexes, effectively inhibiting viral replication. It demonstrates potent antiviral activity with an EC50 value of 0.3 ??g/mL, making it a valuable tool for research into CMV pathogenesis and therapeutic intervention.
重要通知：仅供研究使用。我们不向患者销售。
| Discription | Sevirumab (MSL-109) is a human IgG1 monoclonal antibody designed to neutralize cytomegalovirus (CMV). This antibody specifically targets CMV glycoprotein H (gH) complexes, effectively inhibiting viral replication. It demonstrates potent antiviral activity with an EC50 value of 0.3 ??g/mL, making it a valuable tool for research into CMV pathogenesis and therapeutic intervention. |
||
|---|---|---|---|
| Targets |
|
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2
